PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32477939-0	2020	LncRNA UCA1 Induces Acquired Resistance to Gefitinib by Epigenetically Silencing CDKN1A Expression in Non-small-Cell Lung Cancer.	Gefitinib	43-52	urothelial cancer associated 1	Homo sapiens	7-11	
32477939-4	2020	In the present study, we found that the lncRNA UCA1 was upregulated in NSCLC tissues and cells with acquired gefitinib resistance, indicating the special role of UCA1 in gefitinib resistance.	Gefitinib	109-118	urothelial cancer associated 1	Homo sapiens	47-51	
32477939-4	2020	In the present study, we found that the lncRNA UCA1 was upregulated in NSCLC tissues and cells with acquired gefitinib resistance, indicating the special role of UCA1 in gefitinib resistance.	Gefitinib	170-179	urothelial cancer associated 1	Homo sapiens	47-51	
32477939-4	2020	In the present study, we found that the lncRNA UCA1 was upregulated in NSCLC tissues and cells with acquired gefitinib resistance, indicating the special role of UCA1 in gefitinib resistance.	Gefitinib	170-179	urothelial cancer associated 1	Homo sapiens	162-166	
32477939-5	2020	Knockdown of UCA1 promoted the sensitivity to gefitinib both in vitro and in vivo by suppressing cell proliferation and inducing apoptosis.	Gefitinib	46-55	urothelial cancer associated 1	Homo sapiens	13-17	
32477939-7	2020	Taking the obtained findings together, our study suggests that UCA1 is important for NSCLC to develop gefitinib resistance, and is a potential biomarker for gefitinib resistance and a therapeutic target for advanced NSCLC.	Gefitinib	102-111	urothelial cancer associated 1	Homo sapiens	63-67	
32477939-7	2020	Taking the obtained findings together, our study suggests that UCA1 is important for NSCLC to develop gefitinib resistance, and is a potential biomarker for gefitinib resistance and a therapeutic target for advanced NSCLC.	Gefitinib	157-166	urothelial cancer associated 1	Homo sapiens	63-67	
30784252-0	2019	Knockout of lncRNA UCA1 inhibits drug resistance to gefitinib via targeting STAT3 signaling in NSCLC.	Gefitinib	52-61	urothelial cancer associated 1	Homo sapiens	19-23	
26160838-5	2015	UCA1 knockdown restored gefitinib sensitivity in acquired resistant cells with non-T790M and inhibited the activation of the AKT/mTOR pathway and epithelial-mesenchymal transition (EMT).	Gefitinib	24-33	urothelial cancer associated 1	Homo sapiens	0-4